Tag: Brentuximab Vedotin

Updated efficacy and safety results from Part C of a phase 2 single-arm trial (SGN35-027; ClinicalTrials.gov identifier: NCT03646123; EudraCT 2020-004027-17) evaluating brentuximab vedotin (Adcetris®; Seagen/Takeda)* in combination with the PD-1 inhibitor nivolumab (Opdivo®; Bristol-Myers Squibb) and standard chemotherapy agents doxorubicin (Adriamycin®) and dacarbazine (DTIC-Dome®/Imidazole) for the frontline treatment of patients with early-stage classical Hodgkin lymphoma (cHL).

Compared to Brentuximab Vedotin, Nivolumab Reduces Risk of Disease Progression in Untreated Hodgkin Lymphoma

Pfizer and Seagen have entered into a definitive merger agreement under which Pfizer will acquire Seagen for US $229 in cash per Seagen share...

Antibody-drug conjugates have achieved commercial success over the last 10 years with 15 therapies launched globally to date, including 11 with U.S. FDA approval, and two biosimilars. With their ability to direct highly potent cytotoxic payloads selectively to target cells, ADCs offer the prospect of more precise treatments and a reduction in off-target effects.

Diffuse large B-cell lymphoma (DLBCL), the most common type of an aggressive form of non-Hodgkin lymphoma (NHL) in the United States and worldwide, is...

Presentations discussing brentuximab vedotin (Adcetris®; Seagen/Takeda) presented during the 62nd American Society of Hematology (ASH) Annual, Meeting, and Exposition, held virtually from December 5...

During the upcoming 35th annual meeting of the Society for Immunotherapy of Cancer’s (SITC) being held November 9-14, 2020, Seagen (previously known as Seattle...

Updated and long-term follow-up analyses from two clinical trials evaluating brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda) and nivolumab (Opdivo®; Bristol‑Myers Squibb) in frontline Hodgkin lymphoma...

With the 61st annual meeting of the American Society of Hematology about to begin, here are some of the presentations to look for. This year...

Health Canada has approved the supplemental New Drug Submission that expands the use of brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda) in combination with CHP (cyclophosphamide,...